STOK Stock Forecast: Stoke Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$27
−0.45% on the day

The 14 Wall Street analysts covering Stoke Therapeutics, Inc. hold a median 12-month price target of $43 — +60.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 43 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$1.8B
Ticker Nerd rank
43/ 100
Median analyst target
$43
Analysts covering
14
Revenue$9.3M−32.5% y/y
Operating income−$65.4M
Net income−$61.6M
Free cash flow−$58.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.5%
1M
+0.8%
YTD
−15.5%
1Y
−4.0%
From 52W high
−30.1%
From 52W low
+19.2%
$23
$38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Stoke Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
43/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
77
Value
67
Momentum
67
Accruals
65
Quality
51
Issuance
45
Revisions
36
Growth
15

Volatility (77): The share price has been relatively steady.

Growth (15): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

STOK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STOK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26STOKHigh $60Median $43Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14
Buy
0
Hold
0
Sell
$35
Low
$43
Median
$60
High

The green dot is the last close — the median target sits +60.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Aug 2026JP MorganReinstatesOverweight$40
4 Aug 2026Canaccord GenuityMaintainsBuy$60 → $58
4 Aug 2026Chardan CapitalMaintainsBuy$35
4 Aug 2026GuggenheimReiteratesBuy$60
4 Aug 2026WedbushMaintainsOutperform$38 → $40
13 July 2026Goldman SachsInitiatesBuy$44
11 May 2026BTIGReiteratesBuy—
20 Mar 2026Canaccord GenuityMaintainsBuy—
19 Mar 2026BTIGReiteratesBuy—
18 Mar 2026Chardan CapitalMaintainsBuy—
18 Mar 2026WedbushMaintainsOutperform—
17 Mar 2026NeedhamMaintainsBuy—
17 Mar 2026WedbushMaintainsOutperform—
24 Feb 2026Wolfe ResearchInitiatesOutperform—
12 Jan 2026WedbushMaintainsOutperform—
5 Jan 2026Canaccord GenuityMaintainsBuy—
5 Jan 2026Chardan CapitalMaintainsBuy—
15 Dec 2025HC Wainwright & Co.MaintainsBuy—
5 Nov 2025BTIGReiteratesBuy—
5 Nov 2025Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for STOK.

Market Radar

This page is one stock. Monday covers all of them.

STOK appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

STOK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Stoke Therapeutics, Inc. returned −4.0% against +6.9% for the S&P 500, dividends included.

STOK vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140Jan 26Apr 26Jul 26Oct 26STOKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

STOK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
64.1×

Cheaper than 4% of US stocks

Price / book
5.1×

Cheaper than 18% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−73.6%

Higher than 17% of US stocks

Return on assets
−42.0%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Stoke Therapeutics, Inc. has a market value of $1.8B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $27.6M. The latest quarter shrank 32.5% year on year.

  • Net income over the same four quarters: −$207.9M, a −753.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$180.7M.

  • Shares outstanding: 62.4M.

  • Stoke Therapeutics, Inc. employs 170 people — $162K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

STOK and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
STOKStoke Therapeutics, Inc.$1.8B43
FTREFortrea Holdings, Inc.$1.8B92
TRAXFirst Tracks Biotherapeutics, Inc.$1.7B4
MAZEMaze Therapeutics, Inc.$1.7B25
VERAVera Therapeutics, Inc.$1.8B37
REPLReplimune Group, Inc.$1.8B63
KRSAKorsana Biosciences, Inc.$1.7B24

Take a look at STOK’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Stoke Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about STOK

What is the STOK stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Stoke Therapeutics, Inc. have a median 12-month price target of $43, with estimates ranging from $35 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STOK stock a buy right now?

Of the 14 analysts covering Stoke Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stoke Therapeutics, Inc. 43 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STOK?

As at 21 Nov 2026, Stoke Therapeutics, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (77 of 100).

Will STOK stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +60.4% from the last close, and Ticker Nerd's factor model ranks Stoke Therapeutics, Inc. 43 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STOK stock forecast for 2030?

No analyst covering Stoke Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STOK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $60 over the next 12 months.

How has STOK stock performed over the past year?

Stoke Therapeutics, Inc. returned -4.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Stoke Therapeutics, Inc. do?

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for severe genetic diseases. Its programs are designed to upregulate protein expression and address the underlying cause of disorders linked to insufficient protein production.

Company

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for severe genetic diseases. Its programs are designed to upregulate protein expression and address the underlying cause of disorders linked to insufficient protein production. The company’s portfolio centers on precision therapies for rare neuromuscular, neurological, and other haploinsufficiency-related conditions, with a strong emphasis on antisense oligonucleotide approaches and targeted gene output modulation. Stoke Therapeutics operates in the genetic medicines and rare disease markets, where its research platform supports the discovery and development of treatments intended to restore healthier levels of naturally occurring proteins. Headquartered in Bedford, Massachusetts, Stoke Therapeutics plays a specialized role in advancing novel therapeutic approaches for patients with complex inherited diseases.

CEO Mr. Ian F. Smith A.C.A., C.P.A. · 170 employees · United States · https://www.stoketherapeutics.com